Literature DB >> 25530342

Dysbindin gene variability is associated with cognitive abnormalities in first-episode non-affective psychosis.

Noemí Varela-Gomez1, Ignacio Mata, Rocio Perez-Iglesias, Jose Manuel Rodriguez-Sanchez, Rosa Ayesa, Mar Fatjo-Vilas, Benedicto Crespo-Facorro.   

Abstract

INTRODUCTION: Dystrobrevin-binding protein 1 gene (dysbindin or DTNBP1) has been associated with schizophrenia and cognitive performance. Its expression in areas implicated in cognition such as the dorsolateral prefrontal cortex, as well as its role in dopaminergic and glutamatergic system, has been replicated by several studies. The main aim of this study was to examine the association between DTNBP1 variability and cognitive performance in a sample of 238 patients with a first episode of a non-affective psychosis.
METHODS: Patients, and a comparison sample of 47 healthy subjects, completed an extensive neuropsychological battery. Five single nucleotide polymorphisms (SNPs) within DTNBP1 (rs2619528, rs2619538, rs3213207, rs2619539 and rs760761) and three haplotypes (GACAC, GAGAC and GTGAC) were analysed.
RESULTS: In the group of patients, we found a significant association between two of the DTNBP1 SNPs and one of the haplotypes (rs2619539, rs3213207 and GACAC) and a measure of premorbid IQ [Wechsler Adult Intelligence Scale-3rd Edition (WAIS-III) Vocabulary subtest]. Moreover, one of these SNPs, rs2619539, was also associated with our measure of working memory (WAIS-III Backward digits subtest) and two haplotypes, GAGAC and GTGAC, with our measure of verbal memory (Rey Auditory Verbal Learning Test), of visual memory (Rey Complex Figure Test) in the case of GAGAC, and of speed of processing (WAIS-III Digit Symbol-coding) in the case of GTGAC.
CONCLUSIONS: Our findings add further evidence suggesting an association between dysbindin gene variability and cognitive abnormalities in schizophrenia, providing preliminary evidence of this association since the time of illness onset among minimally medicated patients.

Entities:  

Keywords:  DTNBP1; cognition; dysbindin; first-episode; psychosis; schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25530342     DOI: 10.1080/13546805.2014.991780

Source DB:  PubMed          Journal:  Cogn Neuropsychiatry        ISSN: 1354-6805            Impact factor:   1.871


  10 in total

1.  Impaired copper transport in schizophrenia results in a copper-deficient brain state: A new side to the dysbindin story.

Authors:  Kirsten E Schoonover; Stacy L Queern; Suzanne E Lapi; Rosalinda C Roberts
Journal:  World J Biol Psychiatry       Date:  2018-12-20       Impact factor: 4.132

2.  Loss of dysbindin-1 affects GABAergic transmission in the PFC.

Authors:  H Trantham-Davidson; A Lavin
Journal:  Psychopharmacology (Berl)       Date:  2019-06-14       Impact factor: 4.530

3.  Dysregulation of Specialized Delay/Interference-Dependent Working Memory Following Loss of Dysbindin-1A in Schizophrenia-Related Phenotypes.

Authors:  Emilie I Petit; Zuzanna Michalak; Rachel Cox; Colm M P O'Tuathaigh; Niamh Clarke; Orna Tighe; Konrad Talbot; Derek Blake; Josephine Joel; Alexander Shaw; Steven A Sheardown; Alastair D Morrison; Stephen Wilson; Ellen M Shapland; David C Henshall; James N Kew; Brian P Kirby; John L Waddington
Journal:  Neuropsychopharmacology       Date:  2016-12-16       Impact factor: 7.853

4.  Abnormalities in the copper transporter CTR1 in postmortem hippocampus in schizophrenia: A subregion and laminar analysis.

Authors:  Kirsten E Schoonover; Charlene B Farmer; Charity J Morgan; Vidushi Sinha; Laura Odom; Rosalinda C Roberts
Journal:  Schizophr Res       Date:  2021-01-09       Impact factor: 4.939

5.  Sleep/Wake Disruption in a Mouse Model of BLOC-1 Deficiency.

Authors:  Frank Y Lee; Huei-Bin Wang; Olivia N Hitchcock; Dawn Hsiao Loh; Daniel S Whittaker; Yoon-Sik Kim; Achilles Aiken; Collette Kokikian; Esteban C Dell'Angelica; Christopher S Colwell; Cristina A Ghiani
Journal:  Front Neurosci       Date:  2018-11-15       Impact factor: 4.677

Review 6.  Verbal memory measurement towards digital perspectives in first-episode psychosis: A review.

Authors:  Can Mişel Kilciksiz; Richard Keefe; James Benoit; Dost Öngür; John Torous
Journal:  Schizophr Res Cogn       Date:  2020-04-15

7.  Consensus on potential biomarkers developed for use in clinical tests for schizophrenia.

Authors:  Ping Lin; Junyu Sun; Xiaoyan Lou; Dan Li; Yun Shi; Zhenhua Li; Peijun Ma; Ping Li; Shuzi Chen; Weifeng Jin; Shuai Liu; Qing Chen; Qiong Gao; Lili Zhu; Jie Xu; Mengyuan Zhu; Mengxia Wang; Kangyi Liang; Ling Zhao; Huabin Xu; Ke Dong; Qingtian Li; Xunjia Cheng; Jinghong Chen; Xiaokui Guo
Journal:  Gen Psychiatr       Date:  2022-02-23

Review 8.  Genetics of methamphetamine use disorder: A systematic review and meta-analyses of gene association studies.

Authors:  Alexandre A Guerin; Eric J Nestler; Michael Berk; Andrew J Lawrence; Susan L Rossell; Jee Hyun Kim
Journal:  Neurosci Biobehav Rev       Date:  2020-11-17       Impact factor: 8.989

9.  Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.

Authors:  Maju Mathew Koola
Journal:  Schizophr Res Cogn       Date:  2016-06

Review 10.  Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond.

Authors:  John L Waddington; Xuechu Zhen; Colm M P O'Tuathaigh
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.